EUCTR2010-021382-78-ES进行中(未招募)不适用
Dose radiotherapy for lung cancer treatment.
适应症
试验速览
- 阶段
- 不适用
- 状态
- 进行中(未招募)
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •a) Men or women who are between 18 and 65 years of age
- •b)Subjects with histologically or cytologically confirmed non-small cell carcinoma
- •c)Stage III
- •d)Karnofsky index = 70 %.
- •e)Forced Expiratory Volume in 1 second (FEV1) equal or greater than 1 Liter.
- •f)Measurable disease on CT scan of radiotherapy planning.
- •g)Lung percentage (both lungs excluding PTV or planned volume) that will recive a dose > 20 Gy (V20 ) must be less or equal of 30 %.
- •h)The esophagus volume vill be delimited withoth excluding PTV. The percentage of esophagus that will recive a dose > 60 Gy (V60) mus be less or equal to 30% and the mean dose in esophagus (MED) less or equal to 34 Gy.
- •i) Concomitanr chemotherapy.
- •j) Biochemistry and blood analysis. Neutrophils = 1500/µl; platelets = 100000/µl; creatinine = 2 mg/dl, hepatic transaminases < 2,5 times the upper limit of normality, bilirubin < 1,5 times upper limit of normality; alkaline phosphatase < 2,5 times the upper limit of normality.
- •k) Women must commit to consistent and correct use of an acceptable method of birth control.
- •l) Subject with a weigth loss <10% in the previous three months of the disgnosis.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 42
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •a)Small-cell carcinoma
- •b)Pleural or pericardic effusion with positive cytology
- •c)Supraclavicular adenopathy positive
- •d)Superior vena cava syndrome
- •e)Previous thoracic radiation.
- •f)Sensitive neuropathy > grade I following NCI CTCv 3.0 criteria
- •g)Severe comorbididy (acute myocardial infacrtion within 3 nmonth of inclusion, cardiac arrithmia or non-controlled hypertension )
- •h)Treatments that can interfere with the pharmacokinetic or pharmacodynamic of (18F)-FMISO.
- •i)Pregnant or breast-feeding females
- •j)Subjects older than 65 years.
- •k)Subjects with renal and/or hepatic function impairment or failure. A renal impairment is considered if serum creatinine = 2 mg/dl and an hepatic impairment is diagnosed if bilirubin = 1,5 times upper limit normal and or tranbaamionas (ASAT-ALAT) = 2,5 times the upper limit of normality.
研究者
相似试验
已完成
不适用
Study of radiation therapy for lung cancer combined with interstitial lung disease in JapaJPRN-UMIN000036846ung and Mediastinal Tumor Committee of Japanese Radiation Oncology Study Group (JROSG)67
尚未招募
2 期
Radiotherapy to lungs for COVID-19 pneumoniaCTRI/2021/05/033868Kolhapur Cancer Centre
已完成
不适用
Clinical study on the treatment of lung cancer related fatigue with deficiency of Qi-blood by traditional Chinese herb medicine combined with AcupunctureITMCTR2000003964Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai University of Traditional Chinese Medicine
已完成
不适用
Treatment of lung cancer - a health care research study using data cancer registry data (registration according to § 65c SGB V)C34Malignant neoplasm of bronchus and lungDRKS00025080niversität zu Lübeck, Institut für Sozialmedizin und Epidemiologie70,804
进行中(未招募)
2 期
A clinical trial to prove the benefit of low dose X-rays to lungs in treating COVID-19 diseaseCTRI/2021/06/034001Sri Venkateswara Institute of Medical Sciences
